These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8097691)

  • 1. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
    Martin U; Sponer G; Strein K
    Drug Metab Dispos; 1993; 21(2):236-41. PubMed ID: 8097691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats.
    Martin U; Doerge L; Stegmeier K; Müller-Beckmann B
    Drug Metab Dispos; 1996 Mar; 24(3):288-92. PubMed ID: 8820418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):111-9. PubMed ID: 1719279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Haemost; 1991 May; 65(5):560-4. PubMed ID: 1908140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Res; 1991 May; 62(3):137-46. PubMed ID: 1909815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma.
    Rijken DC; Groeneveld E; Barrett-Bergshoeff MM
    Thromb Haemost; 1994 Dec; 72(6):906-11. PubMed ID: 7740462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Thromb Haemost; 1991 Nov; 66(5):569-74. PubMed ID: 1725068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction?
    Vincze Z; Brugos B
    Pharmazie; 2008 Mar; 63(3):245-6. PubMed ID: 18444516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
    Martin U; Sponer G; Strein K
    Blood Coagul Fibrinolysis; 1993 Apr; 4(2):235-42. PubMed ID: 8388740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
    Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
    Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat.
    Kuiper J; van de Bilt H; Martin U; van Berkel TJ
    Thromb Haemost; 1995 Dec; 74(6):1501-10. PubMed ID: 8772228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.
    Warshawsky I; Bu G; Schwartz AL
    J Clin Invest; 1993 Aug; 92(2):937-44. PubMed ID: 8349826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Lill H; Rudolph R; Sponer G; Stern A; Strein K
    Z Kardiol; 1990; 79 Suppl 3():167-70. PubMed ID: 2129142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Clin Pharmacol Ther; 1991 Oct; 50(4):429-36. PubMed ID: 1914379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.
    Martin U; Sponer G; Strein K
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):455-61. PubMed ID: 7681508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.